mechanism involves ligand binding to the receptor, heterodimerization with the 9-cis retinoic acid receptor α (RXRα), binding of the PXR/RXRα heterodimer to response elements (REs) of target genes, release of corepressor proteins, and recruitment of coactivators and the general transcription machinery Lehmann et al., 1998; Synold et al., 2001; Kliewer et al., 2002; Kliewer et al., 2003) .
Interactions of several azole antifungals with human PXR have recently been investigated. Clotrimazole, a known inducer of CYP3A4 expression, and its analogues have been found as highly potent ligands of human PXR, which promotes interaction of PXR with steroid receptor coactivator-1 (SRC-1, NCOA1) (Bertilsson et al., 1998; Lehmann et al., 1998; ElSankary et al., 2001; Ekins et al., 2007 and others) . Itraconazole and ketoconazole are weak inducers of CYP3A4 via PXR (Sinz et al., 2006; Huang et al., 2007) . However, ketoconazole was reported to inhibit ligand-induced PXR-mediated transcriptional regulation of CYP3A4 and MDR1 genes (Takeshita et al., 2002; Duret et al., 2006; Huang et al., 2007; Wang et al., 2007) . It has been suggested that the molecular mechanism underlying the inhibition proceeds through specific disruption of PXR interaction with SRC-1 at the AF-2 coactivator binding site (Takeshita et al., 2002; Huang et al., 2007; Wang et al., 2007) . Recently, oxiconazole, miconazole and fluconazole were reported to suppress basal and rifampicin-activated PXR-mediated activation of This article has not been copyedited and formatted. The final version may differ from this version. 5 CYP3A4 (-10,466 to +53) luciferase reporter plasmid in transient transfection assays (Wang et al., 2007) .
In the present study, we focused on effects of azole antimycotics clotrimazole, ketoconazole, econazole, oxiconazole, miconazole, fluconazole and itraconazole on PXRmediated expression of CYP3A4. We investigated potency of the individual azole antimycotics to regulate levels of CYP3A4 mRNA in LS174T cells and primary human hepatocytes employing real-time RT-PCR, transactivate CYP3A4 promoter in gene reporter assays, bind to PXR ligandbinding domain (LBD) and recruit SRC-1 coactivator to PXR in mammalian two-hybrid assays.
Furthermore, we examined effects of tested azoles on rifampicin-induced CYP3A4 transactivation through PXR. Finally, we aimed to describe the nature of potential pharmacodynamic interactions of tested azole antimycotics co-administered with a prototypical PXR ligand rifampicin in transactivation of CYP3A4 gene.
We reveal differential effects of several azole antimycotics on PXR-mediated transactivation of CYP3A4, binding to PXR LBD and recruitment of SRC-1 to PXR. We show additive and antagonistic effects of azole antimycotics on rifampicin-induced PXR-mediated transactivation of CYP3A4. We demonstrate that oxiconazole is one of the most potent inducers of CYP3A4 gene expression via PXR described so far, whose effect in transactivation of CYP3A4 could be competitively antagonized by rifampicin. We also show that ability of some azoles to affect recruitment of SRC-1 to PXR modulates their net effects in transactivation of CYP3A4 both in the absence or presence of rifampicin. We thus suggest that PXR-mediated activation of CYP3A4 promoter is a complex process, whose magnitude is not exclusively determined by binding 
Materials and Methods
Cell Lines. The human Caucasian hepatocyte carcinoma (HepG2), human colon adenocarcinoma (LS174T) and African Green monkey kidney fibroblast (CV-1) cell lines were purchased from the European Collection of Cell Cultures (Salisbury, UK) and were used within 20 passages after delivery and maintained in antibiotic-free Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). In addition, medium of HepG2 cells was supplemented with 1% sodium pyruvate and 1% nonessential amino acids (Sigma-Aldrich, St.
Louis, MO).
LS174T human colonic epithelial tumor cell line is one of very few human-derived cell lines that have inducible CYP3A4 gene and relatively high expression of PXR (Burk et al., 2005; Cerveny et al., 2007) . CV-1 cell line was used since it does not express any hepatocyte-specific transcriptional factors.
Chemicals. Rifampicin, charcoal, SR12813 (tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate) and cell culture media were purchased from SigmaAldrich (St. Louis, MO). Phenol red-free media were purchased from Invitrogen/Gibco (Carlsbad, CA). FBS was purchased from PAA (Pasching, Austria Plasmids. A chimeric p3A4-luc reporter construct containing the basal promoter (-362/+53) with the proximal PXR response element (ER6) and the distal xenobiotic responsive enhancer module (XREM)(-7836/-7208) of the CYP3A4 gene 5'-flanking region inserted to pGL3-Basic reporter vector (Promega, Madison, WI) was described by Goodwin et al. (1999 For mammalian two-hybrid assays, we used the mammalian two-hybrid fusion plasmids GAL4-PXR-LBD and VP16-SRC-1-RID, which were a generous gift from Dr. A. Takeshita (Toranomon Hospital, Tokyo, Japan; Takeshita et al., 2002 (Cerveny et al., 2007) . The primer sequences for PXR expression analysis were the following: reverse primer 5'-CTG TGA TGC CGA ACA ACT CC -3'; forward primer 5'-CCC AGC CTG CTC ATA GGT TC-3'. Hypoxanthine-Guanine Phosphoribosyl Transferase (HPRT) gene was used as a housekeeping gene (Cerveny et al., 2007) . PCR conditions specific for each gene were optimized with respect to MgCl 2 concentration and annealing temperature.
All samples were run in triplicates simultaneously with negative controls. Melting-curve analyses were performed in each real-time RT-PCR experiment. Pfaffl´s method was applied for relative quantification of gene expression normalized to a housekeeping gene (Pfaffl, 2001 (Cerveny et al. 2007 ). Hepatocytes were isolated and cultured as previously described (Cerveny et al. 2007 Goodwin et al., 1999) . In parallel with CYP3A4 mRNA level, expression of PXR mRNA was also examined.
As shown in Figure 1A , CYP3A4 mRNA levels were strongly induced by oxiconazole (25-fold), clotrimazole (19-fold), rifampicin (16-fold), miconazole (9-fold) and econazole (9-fold) when compared with control in LS174T cells (n=3). Interestingly, ketoconazole, oxiconazole and miconazole significantly (p<0.05) down-regulated PXR mRNA in LS174T cells (Fig. 1A ).
In agreement, we found that oxiconazole, miconazole and econazole are inducers of CYP3A4 mRNA in primary human hepatocytes ( Fig. 2A and 3A) . Dose-response analysis using nonlinear regression analysis revealed that the xenobiotic concentration required to achieve half-maximum activation of CYP3A4 reporter plasmid (EC 50 ) for oxiconazole was approximately 6.1 µM and calculated maximal fold activation value (I max ) was 21.9. Rifampicin activated the reported construct with This article has not been copyedited and formatted. The final version may differ from this version. 13 the EC 50 value of 1.6 µM and I max of 12.4. Thus, dose-response analysis showed that rifampicin is not able to produce full activation of CYP3A4 reporter plasmid under the used experimental conditions. Oxiconazole was also more potent to activate p3A4-luc reporter after 24-h exposure in HepG2 cells in comparison with rifampicin (data in Fig. 4 ) or another prototypical PXR ligand SR12813 at equimolar concentration of 10 µM (76.8-and 53.7-fold activation to control, respectively) under the same experimental conditions with 300 ng p3A4-luc and 50 ng pSG5-PXR cotransfected per well.
Estimated I max for econazole (14.7) was higher than in case of rifampicin (12.4), clotrimazole (13.9) and miconazole (11.9). EC 50 values of econazole and miconazole were higher in comparison with rifampicin (5.6, 12.3 and 1.6 µM, respectively) ( Fig Oxiconazole activated the reporter plasmid with higher affinity to PXR LBD than rifampicin (EC 50 = 2.9 and 5.6 µM, respectively), whereas maximal activation I max did not differ significantly between these two compounds (3.2 versus 3.4). Econazole and miconazole activated GAL4 reporter plasmid through GAL4 PXR LBD with the EC 50 values of 3.6 and ≥15 µM, and This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2B) .
Surprisingly, we found that ketoconazole dose-dependently inhibited the GAL4 reporter plasmid activation through GAL4 PXR LBD construct with an IC 50 of 17.9 µM and I min of 0.25 (Fig. 2B ).
Fluconazole and itraconazole did not activate the reporter plasmid suggesting no interaction of the compound with PXR LBD at the tested concentrations (dose-response data not shown; Fig.   3B ).
Hence we conclude that oxiconazole, clotrimazole, miconazole, and econazole, but not ketoconazole, itraconazole, and fluconazole efficiently activate CYP3A4 promoter through interaction with PXR LBD (Fig. 2A) . We suggest that clotrimazole is a full agonist of PXR, which is able to produce maximal effect in interaction with GAL4-PXR LBD ( Figure 2B ). On the other hand, rifampicin, oxiconazole, econazole, and miconazole are partial agonists on PXR LBD, which interact with GAL4-PXR LBD with substantial affinity; however, they do not produce maximal activation (Fig. 2B) . Interestingly, we confirmed that ketoconazole induces CYP3A4 mRNA and transactivates CYP3A4 promoter, although it is not an agonist of PXR (Huang et al., 2007) .
In next experiments we addressed two questions arising from the data. First, we studied how azole antimycotics affect rifampicin-induced activation of CYP3A4 promoter. We supposed to observe additive, synergistic or antagonistic pharmacodynamic interactions due to different characteristics of tested azoles to transactivate CYP3A4 promoter via PXR and differential effects of the compounds on SCR-1 recruitment to PXR. Second, we aimed to explain why oxiconazole activates CYP3A4 promoter with higher efficacy in comparison with rifampicin although they This article has not been copyedited and formatted. The final version may differ from this version. Fig. 3A and 4) . We suppose that rifampicin attenuates competitively the effect of oxiconazole, which has higher maximal efficacy (I max ) and EC 50 value to transactivate p3A4-luc reporter plasmid ( Fig. 2A) . Consistently with published data (Huang et al., 2007; Wang et al., 2007) , we found that ketoconazole significantly (p<0.05) decreased rifampicin-mediated activation of CYP3A4 promoter (Fig. 3A) . The inhibitory effect of ketoconazole was more pronounced after 24-h co-incubation of ketoconazole (30 µM) with 10 µM rifampicin (more than 55% reduction of activation, data not shown). Of note, we observed indication of additive interactions in activation of the reporter plasmid by combinations of econazole and miconazole with rifampicin, but not in case of clotrimazole (Fig. 3A) . Fluconazole had no effect on both basal and rifampicin-induced PXR-mediated activation of p3A4-luc (Fig.   3A ). Finally, we observed statistically significant (p<0.05) stimulation of rifampicin-mediated activation of p3A4-luc by itraconazole after 8-and 24-h incubation (Fig. 3A , data for 24 h not shown).
In parallel, we performed gene reporter experiments with empty pGL3-Basic reporter plasmid under the same experimental conditions with all tested compounds. We observed slight Recently, ketoconazole was shown to disrupt the interaction of PXR with SRC-1 resulting in suppression of ligand-induced PXR-mediated induction of CYP3A4 and MDR1 genes (Takeshita et al., 2002; Huang et al., 2007; Wang et al., 2007) .
We used the mammalian two-hybrid assay to evaluate whether tested azoles individually or in combination with rifampicin (10 µM) affect interaction of PXR with SRC-1. Consistent with previous reports Synold et al., 2001; Takeshita et al., 2002; Huang et al., 2007 and others) , rifampicin and clotrimazole significantly (p<0.01) promoted the specific interaction of SRC-1 with PXR after 24-h incubation in HepG2 cells (Fig. 3C ). In agreement with gene reporter data ( Fig. 2A) , the effect of rifampicin plateaued from the concentration of 10 µM (data not shown). Oxiconazole and clotrimazole had stronger effects on interaction of PXR with SRC-1 in comparison with the effect of rifampicin after 24 h of incubation (Fig. 3C ). Econazole and miconazole also yield significant recruitment of SRC-1 to PXR (p<0.05). In agreement with reporter experiments with p3A4-luc plasmid (Fig. 3A) , rifampicin significantly (p<0.05) suppressed oxiconazole-mediated interaction of PXR with SRC-1 (Fig. 3C ). Fluconazole and itraconazole had no effects on recruitment of SRC-1 to PXR in the absence of rifampicin (Fig.   3C ). However, we observed that itraconazole augmented rifampicin-mediated recruitment of SRC-1 to PXR after 8-h and 24-h co-incubation in HepG2 cells. The simulative effect of itraconazole (20 µM) was statistically significant (p<0.01) after 8-h co-incubation (7.7±0.4-fold activation in comparison with the effect of rifampicin alone -4.3±0.1-fold activation), but not after 24-h co-treatment (p<0.07) (data for 24 h in Fig. 3C ). Ketoconazole (20 µM) significantly inhibited rifampicin-induced interaction of PXR and SRC-1 after 24-h incubation, which correlates with recent reports (Takeshita et al., 2002; Huang et al., 2007) . Interestingly, we did not see additive effects of econazole and miconazole in combination with rifampicin on SRC-1 recruitment ( Fig. 3A and 3C ). We thus hypothesis that additional factor (coactivator/corepressor) might underlie the interactions of the azoles with rifampicin in transactivation of CYP3A4.
Based on the data in Figure 3 we can conclude that oxiconazole, clotrimazole, miconazole, and econazole are agonists of PXR, which transactivate CYP3A4 promoter and promote SRC-1 coactivator recruitment. In addition, we indicate that oxiconazole promotes recruitment of SRC-1 to PXR more efficiently than rifampicin and clotrimazole, which consequently results in greater transactivation of CYP3A4 promoter by the azole antimycotic. (Fig. 4A ).
In next experiments we assayed the effects of increasing concentrations of oxiconazole on activation of p3A4-luc in HepG2 cells exposed to fixed concentration of rifampicin (10 µM) (Fig.   4B ). Oxiconazole alone activated p3A4-luc in a dose-dependent manner with the maximal activation at the concentration of 20 µM after 24-h treatment (Fig. 4B) . Combination of 10 µM rifampicin with oxiconazole (20 µM) resulted in significant (p<0.05) additively increase of p3A4-luc activation in comparison with the individual effect of 10 µM rifampicin (Fig. 4B) .
However, the activation by the combination of oxiconazole and rifampicin was significantly lower (p<0.05) than the activation mediated by 20 µM oxiconazole alone (Fig. 4B) . Thus, we demonstrate antagonistic effect of rifampicin on oxiconazole-mediated activation of CYP3A4
promoter. These results confirm our hypothesis that rifampicin and oxiconazole compete for activation of the CYP3A4 promoter.
This article has not been copyedited and formatted. The final version may differ from this version. 2A ). In higher concentration (>5 µM) we supposed additive interactions of rifampicin in combination with econazole or miconazole, since these drugs individually activate p3A4-luc reporter plasmid ( Fig. 2A) .
We found additive effects of both econazole and miconazole in combination with rifampicin in the range of concentrations from 0.5 up to 10 µM (Fig. 5) . The effect was statistically significant (p<0.05) from the 5 µM concentration of rifampicin. We did not observed any clear competitive antagonism by rifampicin in azoles-meditated transactivation of CYP3A4 reporter plasmid.
Induction of CYP3A4 mRNA by Combinations of Azole Antimycotics with
Rifampicin in LS174T cells and primary human hepatocytes.
Next, we tested effects of oxiconazole and itraconazole in combination with rifampicin on CYP3A4 mRNA expression employing real-time RT-PCR in LS174T cell line and/or in primary human hepatocytes. We did not detect any statistically significant effect of oxiconazole (10 µM) We also examined the hypothesis that itraconazole (5 and 10 µM) stimulates rifampicin-mediated induction of CYP3A4 mRNA in primary human hepatocytes after 48-h co-incubation with 10 µM rifampicin as suggested in Figure 3A . We noted variable effect of itraconazole on rifampicinmediated induction of CYP3A4 in primary human hepatocytes from three donors (data not shown), which at the moment does not support the hypothesis.
Ongoing studies with extensive set of primary hepatocytes cultures should elucidate the effects of the azoles on rifampicin-mediated induction of CYP3A4 mRNA.
Oxiconazole Activates CYP3A4 Promoter Specifically through PXR. In order to test whether additional nuclear receptors are involved in strong activation of CYP3A4 promoter by oxiconazole, we performed gene reporter experiments with p3A4-luc reporter plasmid and expression vectors encoding human CAR, VDR, GRα, HNF4α, RXRα and PXR nuclear receptors, which trans-activate CYP3A4 (Martinez-Jimenez et al., 2007) . We observed that oxiconazole (10 µM) stimulated significantly (p<0.01) the reporter activity only in cotransfection with PXR expression plasmid (Fig. 6 ). This activation was relatively weak in CV-1 in comparison with hepatoma HepG2 cells ( Fig. 2A,3A,4 ). This finding corresponds with the absence of HNF4α and possibly additional hepatocyte-specific factors in CV-1 cells, which are essential for maximal transactivation of CYP3A4 promoter Li and Chiang, 2006) . Cotransfection of CV-1 cells with PXR, CAR and VDR expression plasmids also yielded activation of CYP3A4 promoter plasmid in the absence of an exogenous ligand (Fig. 6 ). This
This article has not been copyedited and formatted. The final version may differ from this version. GRα, and HNF4α expression plasmids or their empty expression plasmids pcDNA3 (Fig. 6 ) or pSG5 (data not shown). Interaction of oxiconazole with GRα and CAR has been also examined using pGRE 3 -luc and p2B6(PBREM)-SV40-luc reporter plasmids with appropriate REs for tested nuclear receptors (Cerveny et al., 2007) . These experiments confirm no statistically significant agonistic effect of oxiconazole on GRα and CAR (data not shown). Hence we can conclude that oxiconazole at the 10 µM concentration had negligible effect on activation of p3A4-luc through CAR, VDR, GRα, HNF4α and RXRα nuclear receptors.
Activation of ER6 and DR3 Response Elements by Tested Azole Antimycotics
Correlate with Activation of CYP3A4 Promoter.
Finally we tested activation of chimera reporter plasmids with replicate DR3 and ER6 response elements of CYP3A4 promoter by tested azoles. The ligand-activated PXR forms a heterodimer with RXRs and binds to two central REs of CYP3A4 promoter: the everted repeat separated by 6 bases (ER6) located in the proximal promoter and the direct repeat spaced by 3 bases (DR3) in the distal xenobiotic responsive enhancer module (Bertilsson et al., 1998; Lehmann et al., 1998; Goodwin et al., 1999) . DR3 and ER6 REs synergistically transactivate CYP3A4 gene via PXR and disruption of the REs destroys 80 to 90% of PXR-mediated responsiveness of CYP3A4 promoter (Goodwin et al., 1999) . We supposed that activation of the pDR3-luc and pER6-luc reporter plasmids would correlate with activation of p3A4-luc promoter only on the assumption that no additional cis-acting elements are involved in azole-mediated activation of CYP3A4 promoter.
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We found that activation of ER6 response element with tested azole antimycotics well correlated with activation of p3A4-luc reporter (r 2 = 0.90; P=0.0003) (Fig. 7A) . Similarly, we found correlation between pDR3-luc and p3A4-luc activation with tested azole antimycotics (r 2 = 0.79; P=0.003; F-test) with exception of itraconazole, which activated pDR3-luc and pER6-luc, but not p3A4-luc reporter plasmid (Fig. 7B) . Rifampicin was less efficacious activator of both pDR3-luc and pER6-luc reporter plasmids than oxiconazole, miconazole, econazole and clotrimazole at the concentration of 10 µM under the experimental conditions. Thus, we suggest that oxiconazole activate CYP3A4 promoter via PXR specifically through binding to DR3 and ER6 REs.
Cell viability testing after treatment with azole antimycotics
Several azole antimycotics have been shown to be toxic to HepG2 cells or rat hepatocytes 
Discussion
In the current paper, we reveal differential effects of several azole antimycotics on rifampicin-induced PXR-mediated transactivation of CYP3A4. We describe additive and antagonistic interactions of selected azole antimycotics with rifampicin in the process. We demonstrate that oxiconazole is one of the most potent inducers of CYP3A4 gene expression via PXR described so far, whose effect in transactivation of CYP3A4 could be competitively inhibited by rifampicin. We also found that econazole and miconazole are potent PXR ligands and inducers of CYP3A4, which in co-administration with rifampicin activate CYP3A4 promoter in an additive manner. Itraconazole stimulated activation of CYP3A4 promoter and recruitment of SRC-1 to PXR, although it did not interact with PXR LBD. Clotrimazole, a highly potent PXR ligand, neither affected rifampicin-induced transactivation of CYP3A4 nor produced any interactaction with rifampicin on PXR LBD. We also show that ketoconazole suppressed rifampicin-mediated CYP3A4 transactivation, SRC-1 recruitment to PXR as well as interaction of rifampicin with PXR LDB. On the other hand, ketoconazole induced CYP3A4 mRNA through CYP3A4 promoter REs, albeit it is not an agonist of PXR. Fluconazole did not bind to PXR LBD and had no effect on transactivation of CYP3A4 promoter. We thus show differential effects of tested azoles on PXR-controlled CYP3A4 transactivation and suggest that its magnitude is not et al., 2004) . In the present study, employing dose-response analysis we found that oxiconazole produced greater maximal responding capacity (I max ) to activate CYP3A4 luciferase reporter plasmid in comparison with rifampicin (I max = 21.9 versus 12.4; Fig. 2A ). Rifampicin activated CYP3A4 promoter with lower EC 50 than oxiconazole (1.6 versus 6.1 µM, respectively; Fig. 2A ).
In contrast, employing transactivation assay with GAL4-PXR LBD and pG5luc plasmids, oxiconazole activated the reporter plasmid with higher affinity to PXR LBD than rifampicin (EC 50 = 2.9 and 5.6 µM, respectively), whereas maximal activation did not differ significantly between these two compounds (I max 3.2 versus 3.4). This discrepancy clearly indicates that interaction with PXR LBD does not directly determine the magnitude and character of CYP3A4 promoter transactivation by oxiconazole and rifampicin (Fig. 3) . We hypothesize that additional factors such as recruitment of coactivators, release of corepressors from unliganded PXR, suppression of SHP gene expression, presence of a liver-enriched transcriptional factor, histondeacetylase activity or binding to promoter DNA determine the net effect of PXR ligands to transactivate CYP3A4 promoter.
Dose-response relationships presented in Figure 2 suggest that rifampicin is not able to produce full activation of p3A4-luc and pG5luc reporter plasmids under the used experimental conditions in comparison with other potent PXR ligand clotrimazole and oxiconazole ( Fig. 2A) .
In agreement with our data, PXR ligands such as hyperforin, nifedipine, SR12813, reserpin, o, p'-DDT, fenvalerate, pesticide oxadiazon, herbicide pretilachlor, steroid 3α-hydroxy-5β-pregnane-11,20-dione methanesulfonate and several other compounds have been shown to be by about 20
to 70% more potent at equimolar concentrations than rifampicin in transient transfection assays with different reporter plasmids of CYP3A4 gene or in transactivation assays with GAL4-PXR LBD (Sinz et al., 2006; Lemaire et al., 2007; Bertilsson et al. 1998; Moore et al. 2002 and others) . In our experiments, oxiconazole was by about 60% more potent than rifampicin after 8-h treatment and almost 2-fold more potent after 24-h treatment at the concentration of 20 µM in transient transfection experiment with p3A4-luc, and calculated I max for oxiconazole was higher by 77% than I max for rifampicin (Figure 2A ), which rates oxiconazole among the most potent inducer of CYP3A4 via PXR. A drug that produces maximal possible effect through a receptor is referred to as full agonist and a drug that displays submaximal effectiveness is referred to as a partial agonist. In pharmacodynamic theory, a partial agonist acts also as an antagonist in the presence of a full agonist. When it binds to the receptor, it also occupies the drug-binding site competitively with respect to a full agonist. A higher concentration of a full agonist will be required to produce a maximal effect. We observed this phenomenon in case of co-administration of oxiconazole with rifampicin ( Fig. 3B and 4 ). We also demonstrate that econazole and miconazole are potent ligands of PXR, activators of CYP3A4 promoter and inducers of CYP3A4 mRNA. Their combinations with rifampicin activates CYP3A4 promoter in additive manner since we observed partial summation of their individual effects ( Fig. 3A and 5) . Interestingly, another potent PXR ligand clotrimazole did not elicit any additive effect with rifampicin on CYP3A4 transactivation or recruitment of SRC-1 to PXR (Fig. 3) .
This article has not been copyedited and formatted. The final version may differ from this version. In the current paper, we used HepG2 and CV-1 cell lines, which express no or very low mRNA levels for major uptake and efflux drug transporters, which determine intracellular concentration of drugs and thus their activity in interaction with transcriptional factors (Hilgendorf et al. 2007) . By contrast, in hepatocytes expressing numerous drug transporters, cellular concentration of a PXR ligand may be affected . Interface of drug transporters and nuclear receptors thus should be considered in the final effect of an inducer in hepatocytes.
During preparation of the paper, Wang et al. (2007) Another experimental conditions and approaches should be used to elucidate the conflicting observations.
We suppose that cytotoxicity is another important factor, which can lead to false negative or positive results. Therefore to minimize any cytotoxicity of selected azole compounds we 27 biotransformation of tested compound, although it is very low in HepG2 cells (Rodriguez-Antona et al., 2002) . In addition, 8-h incubation is too short to up/down-regulate any transcriptional factor or nuclear receptors.
CYPs mediated DDIs are one of the most alarming problems in clinical practice and in the pharmaceutical industry (Lin, 2006) . Treatment of serious mycotic infections by systemic azole antifungal agents (itraconazole, fluconazole, ketoconazole, voriconazole) in multimorbid patients is associated with the number of severe DDIs. Recent estimates suggest that as many as 95% of hospitalized patients treated with azole antifungals may receive medications capable of producing a major or moderate pharmacokinetic interactions (Bates and Yu, 2003) .
It is generally known that CYPs inhibition is the basis of DDIs mediated by azole antimycotics (Venkatakrishnan et al., 2000) . The inhibitory capability of azoles stems from their mechanism of action, which is inhibition of fungal CYPs-mediated synthesis of ergosterol. As a result, the azole antifungals interact also with human cytochrome P450 and cause DDIs with a large number of drug classes, including antineoplastics, steroids, antimicrobials, antiretrovirals, cardiovascular agents, psychotropics and oral contraceptives (Venkatakrishnan et al., 2000; Shakeri-Nejad and Stahlmann, 2006 This article has not been copyedited and formatted. The final version may differ from this version. 
